Navigation Links
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.,Phase I REOLYSIN Trial

CALGARY, June 05, 2007 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announced today positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers. The results indicate that REOLYSIN(R) can be delivered systemically to patients with advanced and metastatic cancers and cause anti-tumour activity.

"REOLYSIN(R) administered as a one-hour infusion on a monthly schedule is safe and well-tolerated even in multiple doses," said Principal Investigator Dr. Sanjay Goel of the Montefiore Medical Center and Albert Einstein College of Medicine, New York. "This preliminary data suggests there is anti-tumour activity of REOLYSIN(R) administered as a single agent, and warrants further studies either alone or in combination with cytotoxic chemotherapy, which are currently being planned."

A total of 18 patients were treated in the escalating dosage trial to a maximum daily dose of 3x10(10) TCID(50) in a one-hour infusion. Of the 18 patients treated, eight demonstrated stable disease as measured by RECIST (Response Evaluation Criteria in Solid Tumours) including a patient with progressive breast cancer who experienced a 28.5% shrinkage in tumour volume. The trial was originally designed to demonstrate the safety of a single, one-hour infusion of REOLYSIN(R). During the treatment of the 4th cohort of patients however, Oncolytics applied for and was granted approval to allow subsequent patients to receive repeat monthly treatments of REOLYSIN(R). Of the patients eligible for retreatment, three patients received a range of two to seven one-hour infusions of REOLYSIN(R).

Toxicities possibly related to REOLYSIN(R) treatment in this trial were generally mild (grade 1 or 2) and included chills, fever and fatigue.

The primary objective of the Company's U.S. Phase I trial is to determine the maximum tolerated dose,
'"/>




Page: 1 2 3

Related medicine technology :

1. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
(Date:10/13/2008)... from Multiple Cancer Populations Facilitates ..., Mich., Oct. 13 /- Rubicon Genomics,...rick to amplify DNA samples for The,Cancer Atlas G...amplify and standardize total genomic,DNA from 3,0...The Rubicon,GenomePlex(TM) Whole Genome Amplificat...
(Date:10/12/2008)...lone and in Combination with Chemotherapy, FREMON...icals, Inc., a,development-stage pharmaceutical co...rence (RNAi)-based therapeutics, today announced t...on efficacy of siRNA targeting,its proprietary tar...) in,the edition dated October 1, 2008. The paper,...
(Date:10/12/2008)...NGTON, Oct. 12 /- Boston,Sc... results from an analysis,of nearly 7,500 patients...re designed to confirm the performance of the TAXU...t System in real-world practice. The,two-year pool... clinical,restenosis in patients with diabetes as ...
(Date:10/10/2008)...t. 10 /- Diplomat Specialty,Pharmacy ...d Diplomat,Specialty Pharmacy to be one of only th...l Therapy Optimization Study for Multiple Sclerosi...dy, is to examine the benefits of a,specialty phar...erence and,patient outcomes. Targeted patient outc...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 1Allscripts to Announce First Quarter 2008 Results on April 30 17431 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 1Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 2Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 4DURECT to Participate in Morgan Stanley Global Healthcare Conference 17424 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 2
... 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics...ase III multi- center clinical studies of ferumoxy... will be presented during,the National Kidney Foun...place April 10th through 14th in Orlando, Florida....be presented on,Wednesday, April 11, 2007 at appro...
...wed Complete Response or Reduction of,Lesion Size ... 05, 2007 /PRNewswire-FirstCall/ - Nventa,Biopharm...ation of,positive results from a clinical trial ex...spE7, an investigational therapeutic,vaccine for h...en,with the highest grade of cervical dysplasia (C...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6
(Date:10/10/2008)...gency of Record, CHICAGO, Oct. 10 /PRNewswire/ --...e launch of its "Delivering Small Miracles" campai...ng commitment to providing the highest,level of se...ecial Care,Nursery and Mother/Baby units., The ca...c relations and,advertising via billboards, geogra...
(Date:10/10/2008)...tCall/ -- Synvista,Therapeutics, Inc. (Amex: SYI ...ederici, 49, to its Board of Directors, expanding ...est Pharmaceutical Services as Vice President and,...is financial leadership,West Pharmaceutical,s rev...00 million. He has more than 20 years of public ac...
(Date:10/10/2008)...tCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leadin...diagnostics, medical imaging systems and surgical ... of women, today announced plans to release its,fo...Tuesday, November 11,2008 after market close. In ... a conference call on Tuesday, November 11, 2008 a...
(Date:10/10/2008)... NuView Life Sciences Inc.,(NuView) has agreed to ...ce), including operations of the linear accelerato...exas. The Trace facility produces,Copper-64, Coppe...d in,molecular imaging and nuclear medicine. Paul ...e confident that by improving operational,efficien...
Breaking Medicine News(10 mins):Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 2Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 3Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2
...nity-built Riverina Cancer Care Centre is looking ... around reduction in prices, which will bring abou...ike. // This has happened following fears expresse...ople may avoid treatment owing to high costs. Kay ...
...hemselves on the plane to the gulf, not so much fo...s of people in the Gulf. // The demand for rabbit ...nd is much like the oasis in the desert, for what .... Gulf countries are exploring the options of imp...
... with birth defects is improved by incorporation o.... It has been known that folic acid supplementatio...rological birth defects such as spina bifida, anen... the effect of consumption of folic acid fortified...
...March issue of Paediatrics, Children's Hospital Bo...sumption of sugary drinks –home deliveries of nonc...ht loss. // Cara Ebbeling, PhD, and David Ludwig, ... Endocrinology, led the randomized, controlled tri...
Other Medicine News:Health News:A simple answer to teen weight loss: Reducing sugary drinks 2
Substrate Plasma for Factor XII Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XII.
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of Tissue Plasminogen Activator Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests.
Medicine Products: